AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 102 min read$CYTK

Blum Robert I sold $576K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $76.76 ($0.58M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Aug 10, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The newest disclosed fact is the same-day open-market sale of 7,500 shares at $76.76, with holdings after the transaction of 377,820 shares.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 designation generally limits fundamental interpretation.

03

What to watch

The filing does not state tax, diversification, or personal liquidity needs; without context on prior sales cadence, signal strength is limited.

Relevance 4/10Novelty 3/10Timing: filed on 2026-08-10, same day as the reported sale

Background

This is an SEC Form 4 insider transaction for Cytokinetics, Inc. (CYTK) by CEO Robert Blum.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CYTOK insider Form 4 shows CEO Robert Blum sold 7,500 shares at $76.76 on 2026-08-10 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 discloses the transaction size and price, but the presence of a 10b5-1 plan typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No clear sector read-through from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales under 10b5-1 can be purely liquidity-driven and may not reflect bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    Company whose insider transaction is disclosed on Form 4.

  • insider
    Blum Robert I

    President and CEO who sold shares under a Rule 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min